Nektar Therapeutics Status
The company (NASDAQ: NKTR) received $1.85 billion of development capital from Bristol-Myers Squibb on August 8, 2018.
Developer of bio-pharmaceutical medicines created to offer new pathways that treat serious and widespread unmet medical needs. The company's bio-pharmaceutical products include investigational drugs which are used for the treatment of cancer, auto-immune disease and chronic pain, enabling patients to recover from chronic illness.
Year Founded
1990
Employees
509
RevenueTTM 3Q2018
$1.2 B
Net IncomeTTM 3Q2018
$745.7 M
General Information
-
Website
-
Business Status
Profitable
-
Ownership Status
Publicly Held
-
Financing Status
Corporate Backed or Acquired
Nektar Therapeutics News and Updates
Should You Review Recent Insider Transactions At Nektar Therapeutics (NASDAQ:NKTR)?
Simply Wall St | July 9, 2020
Interesting NKTR Call Options For August 28th
Nasdaq | July 9, 2020
Gram-Negative Bacterial Infection Market Growth Overview and Estimates Market Size by 2025
3rd Watch News | July 9, 2020
Nektar Therapeutics's Feed
Nektar Therapeutics's Verticals
Nektar Therapeutics Primary Industry Sector / Group / Code
Nektar Therapeutics's Trends
Nektar Therapeutics Metrics
Growth Rate
SimilarWeb Unique Visitors
Majestic Referring Domains
Twitter Followers
Headquarters
-
HQ Address Line 1455 Mission Bay Boulevard South
-
HQ CitySan Francisco
-
HQ State/ProvinceCalifornia
-
HQ Post Code94158
-
HQ CountryUnited States
Nektar Therapeutics's Keywords
Add a review